| Literature DB >> 35889950 |
Jun-Hyuk Lee1,2, Soyoung Jeon3, Hye Sun Lee3, Yu-Jin Kwon4.
Abstract
This study aimed to determine the optimal cutoff value of waist circumference (WC) for predicting incident NAFLD. In this community-based prospective cohort study, we analyzed data from 5400 participants without NAFLD at baseline aged 40-69 years. NAFLD was defined as a NAFLD-liver fat score >-0.640. A Cox proportional hazards regression model was used to estimate the hazard ratio (HR) and 95% confidence interval (CI) for an association between body composition and NAFLD incidence. The predictive power of each body composition indicator was assessed by Harrell's concordance index for Cox models. During a mean follow-up period of 12 years, there were 2366 new-onset NAFLD events. Compared with men with WC < 81 cm, the adjusted HR (95% CI) for incident NAFLD in those with WC ≥ 81 cm was 2.44 (2.23-2.67). Compared with women with WC < 78.5 cm, the adjusted HR (95% CI) for incident NAFLD in those with WC ≥ 78.5 cm was 2.54 (2.25-2.87). WC was the most significant risk factor for predicting incident NAFLD among body composition indicators in middle-aged and older Korean adults. The optimal WC cutoff point for predicting incident NALFD was 81 cm in men and 78.5 cm in women, which might assist in the early detection and prevention of NAFLD.Entities:
Keywords: abdominal obesity; body mass index; non-alcoholic fatty liver disease; waist circumference
Mesh:
Year: 2022 PMID: 35889950 PMCID: PMC9323785 DOI: 10.3390/nu14142994
Source DB: PubMed Journal: Nutrients ISSN: 2072-6643 Impact factor: 6.706
Figure 1Flow chart of the study population.
Baseline characteristic of the study population.
| Variables | Total ( | Men ( | Women ( |
|
|---|---|---|---|---|
| Age, years | 51.7 ± 8.8 | 52.1 ± 8.8 | 51.3 ± 8.8 | 0.001 |
| WC, cm | 80.0 ± 8.1 | 81.2 ± 6.9 | 79.1 ± 8.7 | <0.001 |
| Body fat, % | 26.3 ± 7.2 | 20.4 ± 4.9 | 30.5 ± 5.3 | <0.001 |
| BMI, kg/m2 | 23.9 ± 2.9 | 23.5 ± 2.6 | 24.1 ± 3.0 | <0.001 |
| TMM, kg | 42.0 ± 7.6 | 48.8 ± 6.0 | 37.2 ± 4.2 | <0.001 |
| Height-adjusted TMM, kg/m2 | 16.5 ± 1.7 | 17.6 ± 1.5 | 15.7 ± 1.2 | <0.001 |
| BMI-adjusted TMM, m2 | 1.8 ± 0.3 | 2.1 ± 0.2 | 1.6 ± 0.2 | <0.001 |
| Body weight, kg | 60.5 ± 9.1 | 65.1 ± 8.8 | 57.2 ± 7.8 | <0.001 |
| Smoking status, | <0.001 | |||
| Non-smoker | 3561 (66.8) | 578 (25.9) | 2983 (96.2) | |
| Ex-smoker | 683 (12.8) | 653 (29.3) | 30 (1.0) | |
| Intermittent smoker | 114 (2.1) | 89 (4.0) | 25 (0.8) | |
| Every day smoker | 973 (18.3) | 910 (40.8) | 63 (2.0) | |
| Physical activity, | <0.001 | |||
| Low (< 7.5 METS-h/wk) | 392 (7.6) | 121 (5.6) | 271 (8.9) | |
| Moderate (7.5–30 METS-h/wk) | 3148 (60.6) | 1241 (57.8) | 1907 (62.7) | |
| High (> 30 METS-h/wk) | 1651 (31.8) | 787 (36.6) | 864 (28.4) | |
| Alcohol drinking, yes, | 2305 (43.0) | 1440 (64.7) | 865 (27.7) | <0.001 |
| Total energy intake, kcal/day | 1937.1 ± 706.1 | 1997.7 ± 665.8 | 1894.1 ± 730.4 | <0.001 |
| MBP, mmHg | 94.0 ± 12.6 | 95.6 ± 11.9 | 92.8 ± 13.0 | <0.001 |
| FPG, mg/dL | 82.6 ± 11.8 | 84.3 ± 12.6 | 81.4 ± 11.1 | <0.001 |
| Insulin, μU/mL | 6.3 (4.8;8.2] | 5.8 (4.5;7.5) | 6.7 (5.2;8.7) | <0.001 |
| TC, mg/dL | 188.0 ± 33.6 | 189.3 ± 33.8 | 187.0 ± 33.4 | 0.0142 |
| TG, mg/dL | 119.0 (92.0;156.0) | 128.0 (98.0;171.0) | 113.0 (88.0;147.0) | <0.001 |
| HDL-C, mg/dL | 46.1 ± 9.9 | 44.4 ± 9.5 | 47.2 ± 10.0 | <0.001 |
| CRP, mg/dL | 0.23 ± 0.60 | 0.24 ± 0.51 | 0.22 ± 0.65 | 0.185 |
| ALT, IU/L | 22.1 ± 8.8 | 25.9 ± 10.0 | 19.5 ± 6.8 | <0.001 |
| AST, IU/L | 26.4 ± 6.9 | 28.1 ± 7.4 | 25.2 ± 6.2 | <0.001 |
| Steroid medication, | 5 (0.1) | 1 (0.0) | 4 (0.1) | 1.000 |
| Anticonvulsant medication, | 3 (0.0) | 2 (0.1) | 1 (0.0) | 1.000 |
| HTN medication, | 351 (6.5) | 110 (4.9) | 241 (7.6) | 0.014 |
| DM medication | 13 (0.2) | 10 (0.4) | 3 (0.1) | 1.000 |
| Dyslipidemia medication, | 10 (0.2) | 7 (0.3) | 3 (0.1) | 0.790 |
Data are presented as mean ± standard deviations for continuous variables and number (%) for categorical variables. Abbreviations: WC, waist circumference; BMI, body mass index; TMM, total muscle mass; MBP, mean blood pressure; FPG, Fating plasma glucose; TC, total cholesterol; TG, triglyceride; HDL-C, high-density lipoprotein cholesterol; CRP, C reactive protein; ALT, alanine aminotransferase; AST, aspartate aminotransferase; HTN, hypertension; DM, diabetes mellitus.
Hazard ratio and 95% confidence interval for incident non–alcoholic fatty liver diseases according to five body composition indices.
| Total | Univariable Model | Multivariable Model 1 | Multivariable Model 2 | Multivariable Model 3 | ||||
|---|---|---|---|---|---|---|---|---|
| HR (95% CI) |
| HR (95% CI) |
| HR (95% CI) |
| HR (95% CI) |
| |
| WC, cm | 1.07 (1.07–1.08) | <0.001 | 1.07 (1.07–1.08) | <0.001 | 1.07 (1.07–1.08) | <0.001 | 1.07 (1.06–1.07) | <0.001 |
| Body fat, % | 1.05 (1.04–1.05) | <0.001 | 1.10 (1.09–1.10) | <0.001 | 1.10 (1.09–1.11) | <0.001 | 1.09 (1.08–1.09) | <0.001 |
| BMI, kg/m2 | 1.21 (1.19–1.22) | <0.001 | 1.22 (1.20–1.23) | <0.001 | 1.22 (1.20–1.24) | <0.001 | 1.19 (1.18–1.21) | <0.001 |
| TMM/Ht2, kg/m2 | 1.21 (1.18–1.24) | <0.001 | 1.37 (1.33–1.41) | <0.001 | 1.38 (1.33–1.42) | <0.001 | 1.32 (1.28–1.36) | <0.001 |
| TMM/BMI | 0.56 (0.49–0.64) | <0.001 | 0.20 (0.16–0.24) | <0.001 | 0.19 (0.15–0.24) | <0.001 | 0.26 (0.20–0.33) | <0.001 |
| Men | ||||||||
| WC, cm | 1.09 (1.08–1.10) | <0.001 | 1.09 (1.08–1.10) | <0.001 | 1.10 (1.09–1.11) | <0.001 | 1.09 (1.08–1.10) | <0.001 |
| Body fat, % | 1.09 (1.08–1.10) | <0.001 | 1.09 (1.08–1.11) | <0.001 | 1.10 (1.09–1.11) | <0.001 | 1.09 (1.07–1.10) | <0.001 |
| BMI, kg/m2 | 1.23 (1.20–1.26) | <0.001 | 1.23 (1.20–1.26) | <0.001 | 1.25 (1.22–1.28) | <0.001 | 1.22 (1.19–1.25) | <0.001 |
| TMM/Ht2, kg/m2 | 1.28 (1.27–1.34) | <0.001 | 1.29 (1.23–1.35) | <0.001 | 1.30 (1.24–1.36) | <0.001 | 1.27 (1.21–1.33) | <0.001 |
| TMM/BMI | 0.33 (0.25–0.44) | <0.001 | 0.27 (0.20–0.37) | <0.001 | 0.24 (0.18–0.34) | <0.001 | 0.34 (0.25–0.48) | <0.001 |
| Women | ||||||||
| WC, cm | 1.07 (1.06–1.07) | <0.001 | 1.06 (1.06–1.07) | <0.001 | 1.06 (1.06–1.07) | <0.001 | 1.06 (1.05–1.07) | <0.001 |
| Body fat, % | 1.10 (1.09–1.12) | <0.001 | 1.10 (1.09–1.11) | <0.001 | 1.10 (1.09–1.11) | <0.001 | 1.09 (1.08–1.10) | <0.001 |
| BMI, kg/m2 | 1.21 (1.19–1.23) | <0.001 | 1.21 (1.19–1.23) | <0.001 | 1.20 (1.18–1.23) | <0.001 | 1.18 (1.16–1.21) | <0.001 |
| TMM/Ht2, kg/m2 | 1.38 (1.32–1.44) | <0.001 | 1.417 (1.36–1.48) | <0.001 | 1.42 (1.36–1.48) | <0.001 | 1.36 (1.30–1.42) | <0.001 |
| TMM/BMI | 0.11 (0.08–0.14) | <0.001 | 0.13 (0.10–0.18) | <0.001 | 0.14 (0.10–0.19) | <0.001 | 0.18 (0.13–0.25) | <0.001 |
Abbreviations: HR, hazard ratio; CI, confidence interval; WC, waist circumference; BMI, body mass index; TMM, total muscle mass. Model 1: adjusted for age and sex (for total); Model 2: adjusted for variables used in Model 1 plus alcohol drinking status, smoking status, physical activity, and total calorie; Model 3: adjusted for variables used in Model 2 plus mean blood pressure, fasting plasma glucose level, serum total cholesterol, CRP, and ALT levels.
Figure 2Harrell’s concordance index and 95% Confidence intervals for predicting NAFLD incidence of five different body composition indices. (a) Unadjusted model in total population, men and women, (b) Adjusted for age, sex (in total), smoking status, alcohol drinking status, physical activity, total calorie intake, mean blood pressure, fasting plasma glucose, CRP, and alanine aminotransferase in total participants, men and women. Abbreviation: BF, Body fat; BMI, Body mass index; CRP, C-reactive protein; TMM/Ht2; Total muscle mass divided by squared of height; TMM/BMI, Total muscle mass divided by body mass index
Figure 3Kaplan–Meier curve for evaluating incident NAFLD identified by waist circumference cutoff points. (a) Total participants, < 80.2 cm (blue line) vs. ≥ 80.2 cm (red dot line), (b) Men, < 81 cm (blue line) vs. ≥ 81 cm (red dot line), (c) Women, < 78.5 cm (blue line) vs. ≥ 78.5 cm (red dot line).
Cox regression analysis for incidence of non–alcoholic fatty liver diseases according to the optimal waist circumference values by sex.
| Unadjusted | Model 1 | Model 2 | Model 3 | ||||||
|---|---|---|---|---|---|---|---|---|---|
| HR (95% CI) |
| HR (95% CI) |
| HR (95% CI) |
| HR (95% CI) |
| ||
| Total | WC | ||||||||
| < 80.2 | reference | reference | reference | reference | |||||
| ≥80.2 | 2.75 (2.53–2.99) | <0.001 | 2.76 (2.53–3.01) | <0.001 | 2.76 (2.53–3.02) | <0.001 | 2.44 (2.23–2.67) | <0.001 | |
| Men | WC | ||||||||
| <81 | reference | reference | reference | reference | |||||
| ≥81 | 2.88 (2.50–3.32) | <0.001 | 2.87 (2.50–3.31) | <0.001 | 2.99 (2.58–3.46) | <0.001 | 2.65 (2.28–3.08) | <0.001 | |
| Women | WC | ||||||||
| <78.5 | reference | reference | reference | reference | |||||
| ≥78.5 | 2.93 (2.62–3.28) | <0.001 | 2.77 (2.47–3.12) | <0.001 | 2.77 (2.45–3.13) | <0.001 | 2.54 (2.25–2.87) | <0.001 | |
Abbreviations: WC, waist circumference; HR, hazard ration; CI, confidence interval. Model 1: adjusted for age and sex (for total); Model 2: adjusted for variables used in Model 1 plus alcohol drinking status, smoking status, physical activity, and total calorie; Model 3: adjusted for variables used in Model 2 plus mean blood pressure, fasting plasma glucose level, serum total cholesterol, CRP, and ALT levels.